<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Epidemiol</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Epidemiol</journal-id><journal-title-group><journal-title>European Journal of Epidemiology</journal-title></journal-title-group><issn pub-type="ppub">0393-2990</issn><issn pub-type="epub">1573-7284</issn><publisher><publisher-name>Springer Netherlands</publisher-name><publisher-loc>Dordrecht</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39680357</article-id><article-id pub-id-type="pmc">PMC11680655</article-id>
<article-id pub-id-type="publisher-id">1180</article-id><article-id pub-id-type="doi">10.1007/s10654-024-01180-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cohort Profile</subject></subj-group></article-categories><title-group><article-title>Cohort profile: Guangzhou breast cancer study (GBCS)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Na</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Cheng Kun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Shu Shu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Min Jie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Xiao Yi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Ze Fang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0537-922X</contrib-id><name><surname>Xu</surname><given-names>Lin</given-names></name><address><email>xulin27@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0064kty71</institution-id><institution-id institution-id-type="GRID">grid.12981.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id><institution>School of Public Health, </institution><institution>Sun Yat-Sen University, </institution></institution-wrap>74 Zhongshan 2nd Road, Guangzhou, Guangdong Province China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zhqgq86</institution-id><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 2757</institution-id><institution>School of Public Health, </institution><institution>The University of Hong Kong, </institution></institution-wrap>Hong Kong, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03angcq70</institution-id><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Institute of Applied Health Research, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff><aff id="Aff4"><label>4</label>Greater Bay Area Public Health Research Collaboration, Guangzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>39</volume><issue>12</issue><fpage>1401</fpage><lpage>1410</lpage><history><date date-type="received"><day>8</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The Guangzhou Breast Cancer Study (GBCS) is a patient-based prospective cohort study designed to identify risk factors and underlying mechanisms for breast cancer (BC) incidence and prognosis, specifically addressing the need for individualized prevention in South China, where BC incidence is notably high. Based in Guangzhou, China, the GBCS began recruitment in 2008, comprises three complementary studies: the Guangzhou breast cancer cohort with 5471 breast cancer patients, a case&#x02013;control study with 1551 cases and 1605 controls, and an immunohistochemistry (IHC) cohort with 1063 breast cancer patients. Participants are primarily aged 41&#x02013;60&#x000a0;years. Cohort follow-up is conducted every three months in the first year, every six months in the second and third years, and annually thereafter. High follow-up rates have been achieved until 2023, with 73.5% for the Guangzhou breast cancer cohort and 98.6% for the IHC cohort still active. Baseline data collection included demographic characteristics and breast cancer risk factors, while follow-up data included survival, treatment details, disease history, occupational history, post-diagnostic lifestyle, and laboratory measures, including genetic markers, proteins, and environmental exposures. The study encourages global collaborations and invites interested researchers to contact the corresponding author at xulin27@ mail.sysu.edu.cn with specific research ideas or proposals.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10654-024-01180-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Cohort</kwd><kwd>Case-control</kwd><kwd>Immunohistochemistry</kwd></kwd-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of China</institution></funding-source><award-id>82373661</award-id><award-id>81773515</award-id><award-id>82103930</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Jiao</given-names></name><name><surname>Ren</surname><given-names>Ze Fang</given-names></name><name><surname>Xu</surname><given-names>Lin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of Guangdong</institution></funding-source><award-id>2022A1515011546</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Jiao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Pietro Paolo Sanna 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Why was the GBCS set up?</title><p id="Par2">Breast cancer (BC) is the most prevalent cancer and the leading cause of cancer mortality in women globally [<xref ref-type="bibr" rid="CR1">1</xref>], and its burden has been rising over the past decades [<xref ref-type="bibr" rid="CR2">2</xref>]. As of 2022, the World Health Organization (WHO) reported 2.3 million new BC cases and 670,000 related deaths worldwide [<xref ref-type="bibr" rid="CR3">3</xref>]. Although BC can affect women at any age after puberty, its incidence increases with age and significant geographical disparities exist, with higher rates in developed regions compared to less developed areas [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par3">In China, the most populous developing country, rapid economic growth over the past five decades has brought about significant lifestyle and environmental changes, contributing to an increased BC burden. Currently, BC is the most common cancer in Chinese women, account for 12.2% of all new BC cases and 9.6% of BC-related deaths globally [<xref ref-type="bibr" rid="CR5">5</xref>]. South China, in particular, shows the highest incidence of BC in the country [<xref ref-type="bibr" rid="CR6">6</xref>], underscoring the need for region specific strategies to mitigate this rising burden. Furthermore, despite the development of various BC risk prediction models [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], there is limited models tailored for Asian women that incorporate DNA or protein biomarkers [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally, efficient prognostic information is needed to optimize patient care and alleviate the strain on healthcare systems.</p><p id="Par4">To address these challenges, the Guangzhou Breast Cancer Study (GBCS) was established in 2008 with the support of the School of public health, the First and the Second Affiliated Hospitals and the Cancer Center of Sun Yat&#x02010;sen University. The GBCS recruited 9029 patients with breast diseases, including 5471 BC patients for the Guangzhou breast cancer cohort. The whole study also includes a case&#x02013;control study with 1551 BC cases and 1605 controls, as well as an immunohistochemistry (IHC) cohort including 1063 BC patients (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The GBCS aims to elucidate the risk factors and underlying mechanisms of BC incidence and prognosis, ultimately benefiting the local population and contributing to global BC research.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Overview of the Guangzhou breast cancer study (GBCS)</p></caption><graphic xlink:href="10654_2024_1180_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec2"><title>Who is in GBCS?</title><p id="Par5">The GBCS consists of three interrelated studies: a Guangzhou breast cancer cohort, a case&#x02013;control study, and an immunohistochemistry (IHC) cohort, each designed to investigate different aspects of BC in South China.</p><sec id="Sec3"><title>Guangzhou breast cancer cohort</title><p id="Par6">The Guangzhou breast cancer cohort is a patient-based, prospective cohort study designed to explore the risk factors and prognosis of BC in South China. Participants were recruited from the First Affiliated Hospital, Second Affiliated Hospital and Cancer Center of Sun Yat-sen University from October 2008 to January 2018. Initially, 9029 patients with various breast diseases were enrolled in the study, all of whom provided informed consent (Supplementary Table&#x000a0;1<bold>)</bold>. Among these participants, 5471 were confirmed to have BC and met the inclusion criteria for the Guangzhou breast cancer cohort, which included: (a) a pathological diagnosis of primary BC; (b) newly diagnosed cases; and (c) residency in the Pearl River Delta region for at least five years. Exclusion criteria were applied to exclude patients with a history of malignancy or mental illness, those unable to communicate due to severe illness, and those with cognitive impairments. Of these 5471 BC patients, 335 were diagnosed with ductal carcinoma in situ and 5136 had invasive BC.</p></sec><sec id="Sec4"><title>Case&#x02013;control study</title><p id="Par7">In the GBCS case&#x02013;control study focuses on identifying risk factors for the occurrence of BC. From October 2008 to March 2012, 1736 women diagnosed with BC from Guangzhou breast cancer cohort (as mentioned above) were unselectively included as cases. Moreover, cancer-free controls, frequency-matched by age, were selected from women undergoing routine medical examinations at the same hospitals during the same period. The inclusion criteria for controls included the absence of breast malignancy, confirmed by mammography, B-ultrasonography or self-reported, and residency in the Pearl River Delta region for at least 5&#x000a0;years. After excluding individuals diagnosed with other cancers, those with mental illness, and those who declined to complete questionnaires or donate blood samples, the final study included 1551 cases (89.3% participation rate) and 1605 controls (90.5% participation rate).</p></sec><sec id="Sec5"><title>Immunohistochemistry (IHC) cohort</title><p id="Par8">The GBCS IHC cohort investigates the underlying mechanisms of BC progression. This cohort includes 1063 women diagnosed with primary invasive BC, with tumors larger than 1&#x000a0;cm, recruited from the Cancer Center of Sun Yat-sen University between January 2008 and December 2015. Exclusion criteria included a history of other malignant tumors or mental illnesses (such as Alzheimer&#x02019;s disease) and severe illnesses or language difficulties that prevent completion of the questionnaire. Histone modification markers and protein levels in tumor and adjacent tissues were assessed using tissue microarrays (TMAs) and immunohistochemistry.</p></sec><sec id="Sec6"><title>How is the cohort followed&#x000a0;up?</title><p id="Par9">The GBCS cohort employs both active and passive follow-up methods. Active follow-ups are conducted every three months during the first year after diagnosis, either via phone calls or outpatient visits. In the second and the third years, follow-up occur every six months. Thereafter, participants are followed up annually until death. These follow-ups collect vital information, including survival statuses, treatment details, disease history, occupational history, post-diagnostic lifestyle changes, and updated contact details. Detailed follow-up variables are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Passive follow-up is conducted through the hospital&#x02019;s electronic medical record system, which provide authoritative data on disease progression and mortality. This method enables the capture of comprehensive clinical information, such as serum tumor markers, cell types and lipid profile, which are meticulously retrieved from medical records. As of 31 December 2023, at least four rounds of follow-up have been completed for all patients, with 4023 (73.5%) participants of Guangzhou breast cancer cohort and 1048 (98.6%) participants of IHC cohort being successfully followed up.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of follow-up variables in the Guangzhou Breast Cancer Study (GBCS) cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sections</th><th align="left">Variables</th></tr></thead><tbody><tr><td align="left" rowspan="4">Survival statuses</td><td align="left">Recurrence</td></tr><tr><td align="left">Metastasis</td></tr><tr><td align="left">Death</td></tr><tr><td align="left">Other newly diagnosed diseases</td></tr><tr><td align="left" rowspan="4">General treatment</td><td align="left">Radiotherapy</td></tr><tr><td align="left">Chemotherapy</td></tr><tr><td align="left">Surgery</td></tr><tr><td align="left">Endocrine therapy</td></tr><tr><td align="left">Disease history</td><td align="left">Heart disease, hypertension, diabetes, allergies, hyperlipidemia, arthritis, other diseases</td></tr><tr><td align="left">Occupational history</td><td align="left">Type of occupation, daily working hours</td></tr><tr><td align="left">Physical exercise</td><td align="left">Type of activity, weekly activity hours</td></tr><tr><td align="left" rowspan="3">Personal health behaviour</td><td align="left">Smoking status</td></tr><tr><td align="left">Tea</td></tr><tr><td align="left">Sleep habits</td></tr><tr><td align="left" rowspan="5">Serum tumor markers</td><td align="left">CEA</td></tr><tr><td align="left">CA199</td></tr><tr><td align="left">CA125</td></tr><tr><td align="left">CA153</td></tr><tr><td align="left">CA211</td></tr><tr><td align="left" rowspan="5">Cell types</td><td align="left">Eosinophil</td></tr><tr><td align="left">Basophil</td></tr><tr><td align="left">Lymphocyte</td></tr><tr><td align="left">Monocyte</td></tr><tr><td align="left">Neutrophil</td></tr><tr><td align="left" rowspan="4">Lipid markers</td><td align="left">Total cholesterol</td></tr><tr><td align="left">Triglyceride</td></tr><tr><td align="left">High-density lipoprotein</td></tr><tr><td align="left">Low-density lipoprotein</td></tr><tr><td align="left" rowspan="8">Demography</td><td align="left">Name</td></tr><tr><td align="left">Age</td></tr><tr><td align="left">Identity card number</td></tr><tr><td align="left">Address</td></tr><tr><td align="left">Mobile phone number</td></tr><tr><td align="left">Email Address</td></tr><tr><td align="left">Household size</td></tr><tr><td align="left">Menopausal status</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec7"><title>What has been measured?</title><p id="Par10">The GBCS collected a comprehensive range of data through structured questionnaires, clinical records and laboratory assays to investigate BC etiology, progression and outcomes. All GBCS participants completed a structured questionnaire developed by the Breast Cancer Epidemiology Research Group of Vanderbilt University, tailored to reflect current research on BC etiology and the demographic characteristics specific to the Guangdong region. Baseline data were obtained by face-to-face interviews, typically lasting 30&#x02013;60&#x000a0;min [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], and included information on demographic factors, menstrual and reproductive history, disease history, contraceptive use, hormone therapy, dietary history, physical activity, occupational history, personal habits, and family history of cancer. Detailed baseline characteristics of the participants from the questionnaire are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Furthermore, clinical data, such as tumor size, nodal status, clinical stage, and receptors status (i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)), were meticulously retrieved from medical records. Participants fasted for 10&#x02013;12&#x000a0;h before providing blood and urine samples, which were collected under the supervision of trained research assistants and stored at&#x02009;&#x02212;&#x02009;80&#x000a0;&#x000b0;C until further analysis. Each participant was assigned a unique identity number to ensure the accuracy and traceability of the samples.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of questionnaire data collected at baseline in the Guangzhou breast cancer cohort, IHC cohort, and case&#x02013;control study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Exposure category</th><th align="left">Variable/exposure</th></tr></thead><tbody><tr><td align="left" rowspan="5">Past medical history</td><td align="left">Diagnosed breast diseases (specifically itemized)</td></tr><tr><td align="left">Diagnosed tumor</td></tr><tr><td align="left">Diagnosed other diseases (specifically itemized)</td></tr><tr><td align="left">Infection-induced fever</td></tr><tr><td align="left">Dysmenorrhea</td></tr><tr><td align="left" rowspan="4">Menstrual and reproductive history</td><td align="left">Age of menarche</td></tr><tr><td align="left">Parity and breastfeeding history</td></tr><tr><td align="left">Menopause status and associated timing</td></tr><tr><td align="left">Contraceptive history</td></tr><tr><td align="left" rowspan="2">Contraceptive methods and hormone use</td><td align="left">Contraceptive history</td></tr><tr><td align="left">History of hormone-replacement therapy use</td></tr><tr><td align="left">Physical activity</td><td align="left">Physical activity at different ages</td></tr><tr><td align="left" rowspan="6">Dietary history</td><td align="left">Meat</td></tr><tr><td align="left">Taste</td></tr><tr><td align="left">Oils</td></tr><tr><td align="left">Fried food</td></tr><tr><td align="left">The old fire soup</td></tr><tr><td align="left">Herbal tea</td></tr><tr><td align="left" rowspan="4">Personal health behaviour</td><td align="left">Smoking</td></tr><tr><td align="left">Passive smoking</td></tr><tr><td align="left">Alcohol</td></tr><tr><td align="left">Tea</td></tr><tr><td align="left" rowspan="4">Occupational history</td><td align="left">Occupation</td></tr><tr><td align="left">Afternoon nap</td></tr><tr><td align="left">Daily sleep time</td></tr><tr><td align="left">Occupational exposures</td></tr><tr><td align="left">Family history</td><td align="left">Family history of cancers</td></tr><tr><td align="left" rowspan="2">Development history and measurement</td><td align="left">Height</td></tr><tr><td align="left">Weight</td></tr><tr><td align="left" rowspan="11">Demography</td><td align="left">Name</td></tr><tr><td align="left">Age</td></tr><tr><td align="left">Identity card number</td></tr><tr><td align="left">Address</td></tr><tr><td align="left">Mobile phone number</td></tr><tr><td align="left">Email Address</td></tr><tr><td align="left">Occupation</td></tr><tr><td align="left">Household size</td></tr><tr><td align="left">Marital status</td></tr><tr><td align="left">Educational level</td></tr><tr><td align="left">Income</td></tr></tbody></table></table-wrap></p><p id="Par11">A wide range of laboratory variables was measured, including 26 urinary metals, 53 single nucleotide polymorphisms (SNPs), 27 cytokines, 14 histone modification markers, 16 proteins, 4 Epstein-Barr virus (EBV) antibodies, anti-<italic>Toxoplasma gondii</italic> (<italic>T. gondii</italic>) and anti-<italic>Chlamydia trachomatis</italic> (<italic>C. trachomatis</italic>) IgG. Each laboratory variable and the corresponding measurement sample are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Summary of laboratory variables measured in the Guangzhou breast cancer cohort, IHC cohort, and case&#x02013;control study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable categories</th><th align="left">Variables</th><th align="left">Populations</th></tr></thead><tbody><tr><td align="left">Urinary metals</td><td align="left"><p>Batch 1: beryllium, titanium, germanium, niobium, molybdenum, tellurium, platinum, bismuth, vanadium, chromium, cobalt, arsenic, selenium, rubidium, strontium, cadmium, indium, cesium, and thallium</p><p>Batch 2: lithium, manganese, nickel, copper, zinc, barium, lead, vanadium, chromium, cobalt, arsenic, selenium, rubidium, strontium, cadmium, indium, cesium, and thallium</p></td><td align="left"><p>Batch 1: 240 cases and 246 controls</p><p>Batch 2: 445 cases and 495 controls</p></td></tr><tr><td align="left">SNPs</td><td align="left">rs1136410, rs17883901, rs1800871, rs1801133, rs1805087, rs1805414, rs2051579, rs2069705, rs2228611, rs2234693, rs250108, rs28366003, rs2981582, rs3219145, rs3736360, rs3918242, rs6505162, rs8679, rs10889221, rs1078985, rs12644365, rs4976412, rs6926191, rs9485372, rs9383951, rs2471214, rs10107389, rs10511591, rs3176626, rs11033111, rs2046210, rs14192, rs911157, rs1052536, rs1061217, rs1075496, rs1290005, rs1711418, rs1800796, rs2273534, rs2292179, rs2605039, rs3751812, rs3816358, rs3845744, rs6829064, rs8109631, rs10216653, rs10989563, rs11078676, rs12380505, rs17102086, and rs2591592</td><td align="left"><p>1551 cases</p><p>1605 controls</p></td></tr><tr><td align="left">Histone modification markers</td><td align="left">H3K4me2, H3K4me3, H3K9me1, H3K9me2, H3K9me3, H3K27me3, H3K36me3, H4K20me3, H3k9ac, H4k5ac, H4k8ac, H4k12ac, H4K16ac, and H3K18ac</td><td align="left">1061 patients of IHC cohort</td></tr><tr><td align="left">Proteins</td><td align="left">MCM5, FOXA1, ECM1, NDUFAB1, AGR2, Eelfg, Glut, STMN1, Calpain7, CMBL, HID1, ENO1, MLPH, ERK1, MIPEP, and GRB7</td><td align="left">1061 patients of IHC cohort</td></tr><tr><td align="left">Cytokines</td><td align="left">MIP1-&#x003b2;, IL-6, IFN-&#x003b3;, IL-1ra, IL-5, GM-CSF, TNF-&#x003b1;, RANTES, IL-2, IL-1&#x003b2;, Eotaxin, Basic-FGF, VEGF, PDGF-BB, IP-10, IL-13, IL-4, MCP1, IL-8, MIP1-&#x003b1;, IL-10, G-CSF, IL-15, IL-7, IL-12p70, IL-17, and IL-9</td><td align="left"><p>794 cases</p><p>268 controls</p></td></tr><tr><td align="left">EBV antibodies</td><td align="left">IgA antibodies against EBV VCA-p18 and EBNA-1, IgG antibodies against EBV VCA-p18 and EBNA-1</td><td align="left"><p>349 cases</p><p>500 controls</p></td></tr><tr><td align="left">Anti-<italic>T. gondii</italic> IgG</td><td align="left">-</td><td align="left"><p>1121 cases</p><p>400 controls</p></td></tr><tr><td align="left">Anti-<italic>C. trachomatis</italic> IgG</td><td align="left">-</td><td align="left"><p>1121 cases</p><p>400 controls</p></td></tr></tbody></table></table-wrap></p><p id="Par12">The study was in accordance with the Declaration of Helsinki and approved by the Sun Yat-sen University Ethics Committee (Institutional Review Board approval number: 2012&#x02013;8).</p></sec><sec id="Sec8"><title>Urine metal detection</title><p id="Par13">Twenty-six metals were quantified using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7500ce ICP-MS, Agilent Technologies). Before analysis, urine samples were diluted with dilute nitric acid. The quantification of metals was performed by ICP-MS, calibrated with external standards provided by Spex Industries, with internal standards (89Y, 103Rh and 175Lu) added to each sample to ensure accuracy [<xref ref-type="bibr" rid="CR13">13</xref>]. Samples underwent at least three replicate analyses, with rigorous quality control, including matrix blanks and quality-control samples, to avoid cross-contamination and ensure precision.</p></sec><sec id="Sec9"><title>DNA isolation and genotyping</title><p id="Par14">Genomic DNA was extracted from blood samples using the TIANamp Genomic DNA Kit (TianGen Biotech Co., Ltd., Beijing, China). Fifty-three SNPs were genotyped using Sequenom&#x02019;s MassARRAY system (San Diego, California, USA) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Both positive and negative control methods were used for quality control, with 5% of samples being randomly selected for duplicate testing, achieving a 100% concordance rate.</p></sec><sec id="Sec10"><title>Construction of tissue microarray (TMA) and IHC</title><p id="Par15">Histone modification markers and protein levels were evaluated using TMAs and IHC [<xref ref-type="bibr" rid="CR16">16</xref>]. TMAs were proceed through a series of steps, including antigen retrieval, blocking and incubating with specific antibodies. IHC stained sections were then digitally captured using the Pannoramic Scanner and analyzed with CaseViewer software. Staining intensity (scored from 0 to 3) and the percentage of positive strained tumor cells (0%&#x02013;100%) were evaluated by an experienced pathologist blinded to the clinical data.</p></sec><sec id="Sec11"><title>Serological tests</title><p id="Par16">Serum cytokine levels were quantified using the Bio-Plex Pro Human Cytokine 27-plex assay (Bio-Rad, M500KCAF0Y) on a Luminex 200 platform (Luminex Corporation, Austin, TX, USA), allowing for rapid and accurate multiplex detection.</p><p id="Par17">IgA and IgG antibodies against EBV VCA-p18 and EBNA-1 were measured using enzyme-linked immunosorbent assay (ELISA) kits (Zhongshan Bio-Tech, Zhongshan, China) [<xref ref-type="bibr" rid="CR17">17</xref>]. The assays were standardized using a reference serum provided with each kit, with defined optical density (OD) cut-off values determining seropositivity [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par18">Anti-<italic>T. gondii</italic> IgG was measured using commercial ELISA kits (Haitai Biological Pharmaceuticals Co., Ltd, Zhuhai, China) [<xref ref-type="bibr" rid="CR19">19</xref>], with results validated against positive, negative, and critical controls. Similarly, anti-<italic>C. trachomatis</italic> IgG and total IgG were detected using ELISA kits (Savyon diagnostics, Israel and Cusabio Biotech Co, China, respectively), with seropositivity defined as a cut-off index (COI) higher than 1.1. All serological assays were conducted according to the manufacturer&#x02019;s instructions, with blinded assessment to prevent bias in the analysis of case&#x02013;control differences.</p></sec></sec><sec id="Sec12"><title>What has been found?</title><sec id="Sec13"><title>Guangzhou breast <italic>cancer</italic> cohort</title><p id="Par19">Up to 31 December 2023, the cohort has been followed up for a mean of 8.22&#x000a0;years (standard deviation&#x02009;=&#x02009;3.12). The mean age of participants were 47.9&#x000a0;years at baseline, primarily includes pre-menopausal women (62.8%) and women with menarche after 12&#x000a0;years of age (86.9%) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Most participants were married (92.1%) and had a history of breastfeeding (85.8%). Notably, 15% of patients had a family history of BC, 24.3% were overweight or obese (BMI&#x02009;&#x02265;&#x02009;25&#x000a0;kg/m<sup>2</sup> ), and 20.7% were diagnosed at clinical stages III or IV. After a mean follow-up duration of 8.22&#x000a0;years, disease progression was observed in 731 patients (18.2%), and 406 deaths (10.1%) were recorded (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Baseline characteristics of the Guangzhou Breast Cancer Study (GBCS) participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left">Guangzhou breast cancer cohort</th><th align="left" colspan="2">Case&#x02013;control study</th><th align="left"/><th align="left">IHC cohort</th></tr><tr><th align="left">BC patients<break/>(n&#x02009;=&#x02009;5471) (%)</th><th align="left">Cases<break/>(n&#x02009;=&#x02009;1551) (%)</th><th align="left">Controls<break/>(n&#x02009;=&#x02009;1605) (%)</th><th align="left"><italic>P*</italic></th><th align="left">BC patients<break/>(n&#x02009;=&#x02009;1063) (%)</th></tr></thead><tbody><tr><td align="left">Age at diagnosis, years</td><td align="left">47.92&#x02009;&#x000b1;&#x02009;10.74</td><td align="left">48.39&#x02009;&#x000b1;&#x02009;11.46</td><td align="left">48.35&#x02009;&#x000b1;&#x02009;11.38</td><td char="." align="char"/><td align="left">48.46&#x02009;&#x000b1;&#x02009;10.40</td></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;40</td><td align="left">1370 (25.0)</td><td align="left">419 (27.0)</td><td align="left">444 (27.7)</td><td char="." align="char"/><td align="left">254(23.9)</td></tr><tr><td align="left">41&#x02013;60</td><td align="left">3394 (62.1)</td><td align="left">907 (58.5)</td><td align="left">931 (58.0)</td><td char="." align="char"/><td align="left">686(64.6)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;61</td><td align="left">703 (12.9)</td><td align="left">225 (14.5)</td><td align="left">230 (14.3)</td><td char="." align="char">0.919</td><td align="left">122(11.5)</td></tr><tr><td align="left">Menopausal status</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Pre-menopausal</td><td align="left">3344 (62.8)</td><td align="left">928 (60.8)</td><td align="left">864 (54.9)</td><td char="." align="char"/><td align="left">597 (59.3)</td></tr><tr><td align="left">Post-menopausal</td><td align="left">1985 (37.2)</td><td align="left">598 (39.2)</td><td align="left">710 (45.1)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.010</td><td align="left">409 (40.7)</td></tr><tr><td align="left">Educational level</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Below junior school</td><td align="left">2469 (48.1)</td><td align="left">736 (49.9)</td><td align="left">596 (38.2)</td><td char="." align="char"/><td align="left">294 (55.9)</td></tr><tr><td align="left">Senior high school</td><td align="left">1284 (25.0)</td><td align="left">399 (27.1)</td><td align="left">581 (37.2)</td><td char="." align="char"/><td align="left">116 (22.1)</td></tr><tr><td align="left">College or above</td><td align="left">1384 (26.9)</td><td align="left">340 (23.1)</td><td align="left">385 (24.6)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.010</td><td align="left">116 (22.1)</td></tr><tr><td align="left">Age of menarche, years</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;12</td><td align="left">700 (13.1)</td><td align="left">194 (13.0)</td><td align="left">233 (14.9)</td><td char="." align="char"/><td align="left">89 (8.7)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;12</td><td align="left">4633 (86.9)</td><td align="left">1302 (87.0)</td><td align="left">1327 (85.1)</td><td char="." align="char">0.117</td><td align="left">934 (91.3)</td></tr><tr><td align="left">Marital status</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Never married</td><td align="left">180 (3.4)</td><td align="left">64 (4.2)</td><td align="left">62 (4.0)</td><td char="." align="char"/><td align="left">19 (1.8)</td></tr><tr><td align="left">Married</td><td align="left">4904 (92.1)</td><td align="left">1350 (89.5)</td><td align="left">1386 (89.3)</td><td char="." align="char"/><td align="left">978 (94.7)</td></tr><tr><td align="left">Widowed or divorced</td><td align="left">239 (4.5)</td><td align="left">95 (6.3)</td><td align="left">104 (6.7)</td><td char="." align="char">0.857</td><td align="left">36 (3.5)</td></tr><tr><td align="left">Parity</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">0</td><td align="left">333 (6.2)</td><td align="left">125 (8.2)</td><td align="left">117 (7.4)</td><td char="." align="char"/><td align="left">39 (3.8)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;1</td><td align="left">5057 (93.8)</td><td align="left">1391 (91.8)</td><td align="left">1454 (92.6)</td><td char="." align="char">0.410</td><td align="left">979 (96.2)</td></tr><tr><td align="left">BMI, kg/m<sup>2</sup></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;23</td><td align="left">2848 (53.9)</td><td align="left">819 (54.8)</td><td align="left">871 (56.7)</td><td char="." align="char"/><td align="left">514 (51.3)</td></tr><tr><td align="left">23&#x02013;24.9</td><td align="left">1152 (21.8)</td><td align="left">302 (20.2)</td><td align="left">308 (20.0)</td><td char="." align="char"/><td align="left">234 (23.4)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;25</td><td align="left">1281 (24.3)</td><td align="left">374 (25.0)</td><td align="left">358 (23.3)</td><td char="." align="char">0.490</td><td align="left">254 (25.3)</td></tr><tr><td align="left">Breastfeeding history</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">No</td><td align="left">725 (14.2)</td><td align="left">236 (16.8)</td><td align="left">285 (18.7)</td><td char="." align="char"/><td align="left">53 (9.9)</td></tr><tr><td align="left">Yes</td><td align="left">4396 (85.8)</td><td align="left">1166 (83.2)</td><td align="left">1236 (81.3)</td><td char="." align="char">0.179</td><td align="left">485 (90.1)</td></tr><tr><td align="left">Family history</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">No</td><td align="left">4516 (85.0)</td><td align="left">1451 (96.5)</td><td align="left">1509 (97.0)</td><td char="." align="char"/><td align="left">921 (89.5)</td></tr><tr><td align="left">Yes</td><td align="left">795 (15.0)</td><td align="left">52 (3.5)</td><td align="left">47 (3.0)</td><td char="." align="char">0.493</td><td align="left">108 (10.5)</td></tr><tr><td align="left">Clinical stage</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">I/II</td><td align="left">3866 (79.3)</td><td align="left">&#x02013;</td><td align="left">-</td><td char="." align="char"/><td align="left">708 (69.9)</td></tr><tr><td align="left">III/IV</td><td align="left">1010 (20.7)</td><td align="left">&#x02013;</td><td align="left">-</td><td char="." align="char"/><td align="left">305 (30.1)</td></tr><tr><td align="left">ER status</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Negative</td><td align="left">1211 (24.3)</td><td align="left">&#x02013;</td><td align="left">-</td><td char="." align="char"/><td align="left">268 (26.5)</td></tr><tr><td align="left">Positive</td><td align="left">3765 (75.7)</td><td align="left">&#x02013;</td><td align="left">-</td><td char="." align="char"/><td align="left">744 (73.5)</td></tr><tr><td align="left">PR status</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Negative</td><td align="left">1664 (33.5)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">275 (27.2)</td></tr><tr><td align="left">Positive</td><td align="left">3297 (66.5)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">735 (72.8)</td></tr><tr><td align="left">HER2 status</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">Negative</td><td align="left">2616 (54.7)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">554 (61.6)</td></tr><tr><td align="left">Equivocal</td><td align="left">1160 (24.3)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">151 (16.8)</td></tr><tr><td align="left">Positive</td><td align="left">1006 (21.0)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">194 (21.6)</td></tr><tr><td align="left">TNBC</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">No</td><td align="left">4271 (89.8)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">826 (92.3)</td></tr><tr><td align="left">Yes</td><td align="left">485 (10.2)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">69 (7.7)</td></tr><tr><td align="left">Ki-67</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;14%</td><td align="left">1209 (26.4)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">364(36.4)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;14%</td><td align="left">3375 (73.6)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">637(63.6)</td></tr><tr><td align="left">Histological grade</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">I/II</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">710 (73.5)</td></tr><tr><td align="left">III</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td char="." align="char"/><td align="left">256 (26.5)</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>P values are for differences between cases and control in the case&#x02013;control study</p><p><italic>BC</italic> Breast cancer, <italic>IHC</italic> Immunohistochemistry</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Follow-up results of Guangzhou breast cancer cohort and immunohistochemistry (IHC) cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Guangzhou breast cancer cohort (n&#x02009;=&#x02009;4023)</th><th align="left">IHC cohort (n&#x02009;=&#x02009;1048)</th></tr></thead><tbody><tr><td align="left">Mean follow-up year (SD)</td><td align="left">8.22 (3.12)</td><td align="left">8.53 (4.02)</td></tr><tr><td align="left">Overall mortality, n (%)</td><td align="left">406 (10.1%)</td><td align="left">189 (18.0%)</td></tr><tr><td align="left">Disease progression, n (%)</td><td align="left">731 (18.2%)</td><td align="left">270 (25.8%)</td></tr><tr><td align="left">SD: Standard deviation</td><td align="left"/><td align="left"/></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Case&#x02013;control study</title><p id="Par20">In the case&#x02013;control study, participants had a mean age of 48.4&#x000a0;years (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). A higher proportion of controls (45.1%) were post-menopausal compared to cases (39.2%). Education attainment was significantly higher in controls than in cases (P&#x02009;&#x0003c;&#x02009;0.01), whereas other characteristics showed no significant differences (P&#x02009;&#x0003e;&#x02009;0.05).</p></sec><sec id="Sec15"><title>Immunohistochemistry (IHC) cohort</title><p id="Par21">The IHC cohort, with a mean age of 48.5&#x000a0;years, predominantly comprised women aged 41 to 60&#x000a0;years (64.6%) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The distribution of menopausal status, age at menarche and marital status among the participants closely resembled those of the Guangzhou breast cancer cohort. A family history of BC was reported by 10.5% of participants and 21.6% of patients tested positive for HER2 status. 73.5% of patients had a histological grade of I or II. During a mean follow-up of 8.53&#x000a0;years (standard deviation&#x02009;=&#x02009;4.02), disease progression occurred in 270 (25.8%) patients, with 189 deaths (18.0%) recorded (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).</p></sec><sec id="Sec16"><title>Published results</title><p id="Par22">Until to 31 August 2024, the GBCS has published 51 papers on various risk factors related to the occurrence and prognosis of breast cancer, as detailed in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Table&#x000a0;2. Of various factors studies (i.e., genetic factors, metal exposure, clinical characteristics, lifestyles, pathogenic microorganisms and proteins), genetic factors have been a primary focus, with polymorphisms in genes such as <italic>PARP1, ESR1, FGFR2, FGF1, RBFOX2, FTO, IL-6,</italic> and <italic>HSPD1</italic> identified as modifiers of BC risk and survival [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Epigenetic studies within the cohort showed that histone modifications, including H3K9me2, H3K9me3, H3K4me2, H3K27me3, H4K20me3, and H4K16ac, were strongly associated with disease progression and mortality [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>A wayne diagram of factors associated with breast cancer risk and mortality that have been studied by the GBCS*. *The size of the circle represents the number of published articles. The color of the circle represents different categories of research factors</p></caption><graphic xlink:href="10654_2024_1180_Fig2_HTML" id="MO2"/></fig></p><p id="Par23">The associations between urine levels of metal exposure and breast cancer risk have also been evaluated, with findings indicating that higher levels of strontium [odds ratio (OR) (95% confidence interval (CI)) for the highest versus the lowest tertile: 2.24 (1.42&#x02013;3.81)] [<xref ref-type="bibr" rid="CR10">10</xref>] and cadmium [OR (95% CI): 1.16 (1.01&#x02013;1.34)] [<xref ref-type="bibr" rid="CR28">28</xref>] were associated with a higher risk of BC. Conversely, higher selenium [OR (95% CI): 0.50 (0.30&#x02013;0.81)] [<xref ref-type="bibr" rid="CR28">28</xref>], thallium [OR (95% CI): 0.36 (0.21&#x02013;0.60)] [<xref ref-type="bibr" rid="CR29">29</xref>], vanadium [OR (95% CI): 0.60 (0.37&#x02013;0.97)] [<xref ref-type="bibr" rid="CR29">29</xref>], and cesium levels [ORs (95% CI): 0.50 (0.30&#x02013;0.82)] [<xref ref-type="bibr" rid="CR30">30</xref>] were associated with a lower risk of BC, which were consistent with other studies [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par24">Futhermore, we found that long interval (&#x0003e;&#x02009;5&#x000a0;years) between first and second birth was associated with a better progression free survival (PFS) [hazard ratio (HR) (95% CI): 0.64 (0.42&#x02013;0.97)] [<xref ref-type="bibr" rid="CR34">34</xref>], whereas weight loss at 2&#x000a0;years [HR (95% CI): 1.34 (0.87&#x02013;2.06)] or more than 2&#x000a0;years [HR (95% CI): 1.95 (1.22&#x02013;3.10)] after diagnosis increased the risk of BC progression [<xref ref-type="bibr" rid="CR35">35</xref>]. In addition, specific Chinese lifestyles such as taking a nap [<xref ref-type="bibr" rid="CR36">36</xref>] and drinking tea [<xref ref-type="bibr" rid="CR37">37</xref>] appeared to be associated with a lower risk of BC progression.</p><p id="Par25">Infectious agents such as Epstein-Barr virus and <italic>Toxoplasma gondii</italic> infection have also been examined, with results showing that Epstein-Barr virus infection being associated with a higher BC risk among ER&#x02009;+&#x02009;, PR&#x02009;+&#x02009;, and HER2&#x02009;+&#x02009;patients [<xref ref-type="bibr" rid="CR18">18</xref>], while <italic>Toxoplasma gondii</italic>&#x000a0;infection being associated with a lower BC mortality and progression risk [HR (95% CI):0.60 (0.37&#x02013;0.99) for mortality; HR (95% CI):0.67 (0.46&#x02013;0.98) for progression] [<xref ref-type="bibr" rid="CR38">38</xref>]. Specific mechanisms have been demonstrated in cellular experiments [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par26">Additionally, the role of proteins such as FOXA1 in BC prognosis has been characterized, with time-varying effect observed. Specifically, higher FOXA1 expression was initially associated with improved survival rate in the early post-diagnosis period. However, the potential protective effect appeared to diminish over time, eventually giving way to an adverse effect in the later years [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec17"><title>What are the main strengths and weaknesses?</title><p id="Par27">The GBCS represents a unique and comprehensive study in South China, with several strengths. First, the GBCS cohort includes three sub-studies, each focused on investigating distinct aspects of BC, including risk factors, underlying mechanisms and prognostic indicators. This multifaceted approach enables the investigation of BC across the entire disease spectrum, from preventive to treatment. Another strength lies in its extensive and detailed data collection by face-to-face interview using validated questionnaires. This approach captures region-specific risk factors such as socioeconomic conditions, diet habits (tea intake) and lifestyle factors (late sleep timing and napping) at baseline and follow-up. Third, the robust biorepository, which includes blood, urine, and breast carcinoma tissue samples were collected and stored according to standardized protocols, provides valuable resources for future research. This biobank supports advanced analyses such as Mendelian randomization and multi-omics approaches, potentially offering insights into the causal pathways and therapeutic responses in BC. Fourth, the long-term sustainability of the GBCS is supported by continuous funding from the Natural Science Foundation of China and the Science and Technology Planning Project of Guangdong Province, as well as strong institutional collaborations. These factors have contributed to high follow-up rates and minimized attrition. Finally, the extended follow-up period has resulted in a large number of mortality cases, offering opportunities to examine the long-term impacts of risk factors on BC prognosis. However, there are limitations to consider. First, the reliance on self-reported data for lifestyle factors and medical history introduces the potential for recall bias. Additionally, the participants were recruited from three leading hospitals in Guangzhou rather than through random sampling, which may limit the generalizability of findings to other populations. However, random sampling in a hospital-based patient cohort is generally impractical and unlikely to be feasible.</p></sec><sec id="Sec18"><title>Can I get hold of the data? Where can I find out more?</title><p id="Par28">The GBCS seeks and encourages collaboration to maximize the use of research data from all over the world. While the dataset contains sensitive information and is not publicly available for download, researchers with specific ideas or proposals are invited to request access. To initiate a collaboration, interested parties should contact the corresponding author, Professor Lin Xu at xulin27@mail.sysu.edu.cn. Further details about the study and opportunities for collaboration can also be obtained through this contact. </p></sec></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10654_2024_1180_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 85 kb)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are grateful to the participants and the investigators from the Guangzhou Breast Cancer Study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L. X. has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: L. X., J. W. Acquisition, analysis or interpretation of data: all authors. Statistical analysis: J. W., N. L., S. S. H, C. K. X, X. Y. L. and M. J. L. Drafting of the manuscript: J. W., N. L., S. S. H, C. K. X and M. J. L. Critical revision of the manuscript for important intellectual content: L. X. and Z. F. R.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded by the Natural Science Foundation of China [No. 82373661, 82103930 and 81773515] and the Natural Science Foundation of Guangdong [2022A1515011546].</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par29">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par30">The Guangzhou Medical Ethics Committee of the Chinese Medical Association approved the Guangzhou Breast Cancer Study (ID: 2012-8). All participants provided written, informed consent before participation.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Collaboration GBoDC. The Global Burden of Cancer 2013. <italic>JAMA Oncology</italic> 2015; <bold>1</bold>: 505&#x02013;27.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name></person-group><article-title>Global trends and forecasts of breast cancer incidence and deaths</article-title><source>Sci Data</source><year>2023</year><volume>10</volume><fpage>334</fpage><pub-id pub-id-type="doi">10.1038/s41597-023-02253-5</pub-id><pub-id pub-id-type="pmid">37244901</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10:334.<pub-id pub-id-type="pmid">37244901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>E</given-names></name><name><surname>Rumgay</surname><given-names>H</given-names></name><etal/></person-group><article-title>Current and future burden of breast cancer: global statistics for 2020 and 2040</article-title><source>Breast</source><year>2022</year><volume>66</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2022.08.010</pub-id><pub-id pub-id-type="pmid">36084384</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15&#x02013;23.<pub-id pub-id-type="pmid">36084384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x02013;424.<pub-id pub-id-type="pmid">30207593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Strasser-Weippl</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J-J</given-names></name><etal/></person-group><article-title>Breast cancer in China</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>e279</fpage><lpage>e289</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70567-9</pub-id><pub-id pub-id-type="pmid">24872111</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fan L, Strasser-Weippl K, Li J-J, et al. Breast cancer in China. Lancet Oncol. 2014;15:e279&#x02013;89.<pub-id pub-id-type="pmid">24872111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality in China, 2022</article-title><source>J Nat Cancer Center</source><year>2024</year><volume>4</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jncc.2024.01.006</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Nat Cancer Center. 2024;4:47&#x02013;53.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniou</surname><given-names>AC</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><article-title>Risk prediction models for familial breast cancer</article-title><source>Future Oncol</source><year>2006</year><volume>2</volume><fpage>257</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.2217/14796694.2.2.257</pub-id><pub-id pub-id-type="pmid">16563094</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol. 2006;2:257&#x02013;74.<pub-id pub-id-type="pmid">16563094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobi</surname><given-names>CE</given-names></name><name><surname>de Bock</surname><given-names>GH</given-names></name><name><surname>Siegerink</surname><given-names>B</given-names></name><name><surname>van Asperen</surname><given-names>CJ</given-names></name></person-group><article-title>Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?</article-title><source>Breast Cancer Res Treat</source><year>2009</year><volume>115</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s10549-008-0070-x</pub-id><pub-id pub-id-type="pmid">18516672</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009;115:381&#x02013;90.<pub-id pub-id-type="pmid">18516672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Risk prediction models for breast cancer-related lymphedema: A systematic review and meta-analysis</article-title><source>Eur J Oncol Nurs</source><year>2023</year><volume>64</volume><fpage>102326</fpage><pub-id pub-id-type="doi">10.1016/j.ejon.2023.102326</pub-id><pub-id pub-id-type="pmid">37137249</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shen A, Wei X, Zhu F, et al. Risk prediction models for breast cancer-related lymphedema: A systematic review and meta-analysis. Eur J Oncol Nurs. 2023;64: 102326.<pub-id pub-id-type="pmid">37137249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>He</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Urinary strontium and the risk of breast cancer: a case-control study in Guangzhou</article-title><source>China Environ Res</source><year>2012</year><volume>112</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.envres.2011.11.005</pub-id><pub-id pub-id-type="pmid">22172139</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chen LJ, Tang LY, He JR, et al. Urinary strontium and the risk of breast cancer: a case-control study in Guangzhou. China Environ Res. 2012;112:212&#x02013;7.<pub-id pub-id-type="pmid">22172139</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>FM</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Night-shift work, sleep duration, daytime napping, and breast cancer risk</article-title><source>Sleep Med</source><year>2015</year><volume>16</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2014.11.017</pub-id><pub-id pub-id-type="pmid">25794454</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wang P, Ren FM, Lin Y, et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Med. 2015;16:462&#x02013;8.<pub-id pub-id-type="pmid">25794454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>HD</given-names></name><name><surname>Guo</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Allelic expression imbalance polymorphisms in susceptibility chromosome regions and the risk and survival of breast cancer</article-title><source>Mol Carcinog</source><year>2017</year><volume>56</volume><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1002/mc.22493</pub-id><pub-id pub-id-type="pmid">27128794</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lin W, Lin HD, Guo XY, et al. Allelic expression imbalance polymorphisms in susceptibility chromosome regions and the risk and survival of breast cancer. Mol Carcinog. 2017;56:300&#x02013;11.<pub-id pub-id-type="pmid">27128794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilschefski</surname><given-names>SC</given-names></name><name><surname>Baxter</surname><given-names>MR</given-names></name></person-group><article-title>Inductively coupled plasma mass spectrometry: introduction to analytical aspects</article-title><source>Clin Biochem Rev</source><year>2019</year><volume>40</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.33176/AACB-19-00024</pub-id><pub-id pub-id-type="pmid">31530963</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wilschefski SC, Baxter MR. Inductively coupled plasma mass spectrometry: introduction to analytical aspects. Clin Biochem Rev. 2019;40:115&#x02013;34.<pub-id pub-id-type="pmid">31530963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y-H</given-names></name><name><surname>Ren</surname><given-names>J-T</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Polymorphisms in homologous recombination repair genes and the risk and survival of breast cancer</article-title><source>J Gene Med</source><year>2017</year><volume>19</volume><fpage>e2988</fpage><pub-id pub-id-type="doi">10.1002/jgm.2988</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liao Y-H, Ren J-T, Zhang W, et al. Polymorphisms in homologous recombination repair genes and the risk and survival of breast cancer. J Gene Med. 2017;19: e2988.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="book"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>Ong</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>White</surname><given-names>SJ</given-names></name><name><surname>Cantsilieris</surname><given-names>S</given-names></name></person-group><article-title>The MassARRAY&#x000ae; system for targeted SNP genotyping</article-title><source>Genotyping: methods and protocols</source><year>2017</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>77</fpage><lpage>94</lpage></element-citation><mixed-citation id="mc-CR15" publication-type="book">Ellis JA, Ong B. The MassARRAY&#x000ae; system for targeted SNP genotyping. In: White SJ, Cantsilieris S, editors. Genotyping: methods and protocols. New York: Springer; 2017. p. 77&#x02013;94.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QX</given-names></name><name><surname>Yang</surname><given-names>YZ</given-names></name><name><surname>Liang</surname><given-names>ZZ</given-names></name><etal/></person-group><article-title>Time-varying effects of FOXA1 on breast cancer prognosis</article-title><source>Breast Cancer Res Treat</source><year>2021</year><volume>187</volume><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1007/s10549-021-06125-7</pub-id><pub-id pub-id-type="pmid">33604715</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chen QX, Yang YZ, Liang ZZ, et al. Time-varying effects of FOXA1 on breast cancer prognosis. Breast Cancer Res Treat. 2021;187:867&#x02013;75.<pub-id pub-id-type="pmid">33604715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Luo</surname><given-names>RX</given-names></name><etal/></person-group><article-title>Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay: optimization, standardization and diagnostic criteria</article-title><source>Chin Med J</source><year>1998</year><volume>111</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">11245074</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ng MH, Chen HL, Luo RX, et al. Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay: optimization, standardization and diagnostic criteria. Chin Med J. 1998;111:531&#x02013;6.<pub-id pub-id-type="pmid">11245074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>JR</given-names></name><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>Yu</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Epstein&#x02013;Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma</article-title><source>Cancer Lett</source><year>2011</year><volume>309</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.05.012</pub-id><pub-id pub-id-type="pmid">21724319</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">He JR, Tang LY, Yu DD, et al. Epstein&#x02013;Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett. 2011;309:128&#x02013;36.<pub-id pub-id-type="pmid">21724319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>LY</given-names></name><name><surname>Meng</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Seroprevalence and genetic characterization of Toxoplasma gondii in cancer patients in Anhui Province</article-title><source>Eastern China Parasites Vect</source><year>2015</year><volume>8</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1186/s13071-015-0778-5</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wang L, He LY, Meng DD, et al. Seroprevalence and genetic characterization of Toxoplasma gondii in cancer patients in Anhui Province. Eastern China Parasites Vect. 2015;8:162&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of physical activity and polymorphisms in FGFR2 and DNA methylation related genes with breast cancer risk</article-title><source>Cancer Epidemiol</source><year>2014</year><volume>38</volume><issue>6</issue><fpage>708714</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2014.09.002</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Xi J, Su Y, Beeghly Fadiel A, et al. Association of physical activity and polymorphisms in FGFR2 and DNA methylation related genes with breast cancer risk. Cancer Epidemiol. 2014;38(6):708714.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Cen</surname><given-names>YL</given-names></name><name><surname>Qi</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status</article-title><source>Mol Carcinog</source><year>2013</year><volume>52</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1002/mc.21979</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cen YL, Qi ML, Li HG, et al. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog. 2013;52 Suppl 1:E52-59.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Qi</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Effects of passive smoking on breast cancer risk in pre/post-menopausal women as modified by polymorphisms of PARP1 and ESR1</article-title><source>Gene</source><year>2013</year><volume>524</volume><fpage>18489</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2013.04.064</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Tang LY, Chen LJ, Qi ML, et al. Effects of passive smoking on breast cancer risk in pre/post-menopausal women as modified by polymorphisms of PARP1 and ESR1. Gene. 2013;524(2):8489.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>RM</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><fpage>14</fpage></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zhu RM, Lin W, Zhang W, et al. Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival. PLoS ONE. 2017;12:14.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>JQ</given-names></name><name><surname>Chen</surname><given-names>QX</given-names></name><etal/></person-group><article-title>Association of H3K9me3 with breast cancer prognosis by estrogen receptor status</article-title><source>Clin Epigenetics</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/s13148-022-01363-y</pub-id><pub-id pub-id-type="pmid">36303253</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhou M, Yan JQ, Chen QX, et al. Association of H3K9me3 with breast cancer prognosis by estrogen receptor status. Clin Epigenetics. 2022;14(1):135.<pub-id pub-id-type="pmid">36303253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>CK</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group><article-title>H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer</article-title><source>Epigenetics</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>2343593</fpage><pub-id pub-id-type="doi">10.1080/15592294.2024.2343593</pub-id><pub-id pub-id-type="pmid">38643489</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Xiao CK, Ren Y, Chen Q, et al. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer. Epigenetics. 2024;19(1):2343593.<pub-id pub-id-type="pmid">38643489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients</article-title><source>Virchows Arch Int J Pathol</source><year>2023</year><volume>482</volume><issue>6</issue><fpage>1047</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1007/s00428-023-03534-5</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang B, Zhou M, Shi YY, et al. Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients. Virchows Arch Int J Pathol. 2023;482(6):1047&#x02013;1056.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>XL</given-names></name><etal/></person-group><article-title>Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer</article-title><source>Int J Clin Oncol</source><year>2023</year><volume>28</volume><issue>9</issue><fpage>1147</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1007/s10147-023-02378-y</pub-id><pub-id pub-id-type="pmid">37428307</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wang B, Zhou M, Gan XL, et al. Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer. Int J Clin Oncol. 2023;28(9):1147&#x02013;1157.<pub-id pub-id-type="pmid">37428307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>XL</given-names></name><name><surname>He</surname><given-names>JR</given-names></name><name><surname>Cen</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Modified effect of urinary cadmium on breast cancer risk by selenium</article-title><source>Clin Chim Acta Int J Clin Chem</source><year>2015</year><volume>438</volume><fpage>8085</fpage><pub-id pub-id-type="doi">10.1016/j.cca.2014.08.014</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wei XL, He JR, Cen YL, et al. Modified effect of urinary cadmium on breast cancer risk by selenium. Clin Chim Acta Int J Clin Chem. 2015;438:8085.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Urinary titanium and vanadium and breast cancer: a case-control study</article-title><source>Nutr Cancer</source><year>2012</year><volume>64</volume><issue>3</issue><fpage>368</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1080/01635581.2012.654586</pub-id><pub-id pub-id-type="pmid">22332886</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Tang LY, Su Y, He JR, et al. Urinary titanium and vanadium and breast cancer: a case-control study. Nutr Cancer. 2012;64(3):368&#x02013;376.<pub-id pub-id-type="pmid">22332886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>YC</given-names></name><name><surname>Tang</surname><given-names>LY</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of urinary cesium with breast cancer risk</article-title><source>Asian Pac J Cancer Prev APJCP</source><year>2014</year><volume>15</volume><issue>22</issue><fpage>9785</fpage><lpage>9790</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.22.9785</pub-id><pub-id pub-id-type="pmid">25520105</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Qin YC, Tang LY, Su Y, et al. Association of urinary cesium with breast cancer risk. Asian Pac J Cancer Prev APJCP. 2014;15(22):9785&#x02013;9790.<pub-id pub-id-type="pmid">25520105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Orsini</surname><given-names>N</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name><etal/></person-group><article-title>Urinary cadmium concentration and risk of breast cancer: a systematic review and dose-response meta-analysis</article-title><source>Am J Epidemiol</source><year>2022</year><volume>182</volume><issue>5</issue><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1093/aje/kwv085</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Larsson SC, Orsini N, Wolk A. Urinary cadmium concentration and risk of breast cancer: a systematic review and dose-response meta-analysis. Am J Epidemiol. 2015;182(5):375&#x02013;380.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies</article-title><source>Biol Trace Elem Res</source><year>2021</year><volume>199</volume><issue>12</issue><fpage>4439</fpage><lpage>4446</lpage><pub-id pub-id-type="doi">10.1007/s12011-021-02574-9</pub-id><pub-id pub-id-type="pmid">33420696</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhu X, Pan D, Wang N, et al. Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies. Biol Trace Elem Res. 2021;199(12):4439&#x02013;4446.<pub-id pub-id-type="pmid">33420696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Gamboa-Loira</surname><given-names>B</given-names></name><name><surname>M&#x000e9;rida-Ortega</surname><given-names>&#x000c1;</given-names></name><name><surname>Rothenberg</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Metal exposure and breast cancer among Northern Mexican women: assessment of genetic susceptibility</article-title><source>Environ Sci Pollut Res Int</source><year>2022</year><volume>29</volume><issue>59</issue><fpage>89002</fpage><lpage>89013</lpage><pub-id pub-id-type="doi">10.1007/s11356-022-21067-3</pub-id><pub-id pub-id-type="pmid">35841505</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Gamboa-Loira B, M&#x000e9;rida-Ortega &#x000c1;, Rothenberg SJ, et al. Metal exposure and breast cancer among Northern Mexican women: assessment of genetic susceptibility. Environ Sci Pollut Res Int. 2022;29(59):89002&#x02013;89013.<pub-id pub-id-type="pmid">35841505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>MX</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Associations of reproductive factors with breast cancer prognosis and the modifying effects of menopausal status</article-title><source>Cancer Med</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1002/cam4.2707</pub-id><pub-id pub-id-type="pmid">31724329</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhang JY, Wang MX, Wang X, et al. Associations of reproductive factors with breast cancer prognosis and the modifying effects of menopausal status. Cancer Med. 2020;9(1):385&#x02013;393.<pub-id pub-id-type="pmid">31724329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Liang</surname><given-names>ZZ</given-names></name><name><surname>Li</surname><given-names>YQ</given-names></name></person-group><article-title>Association between weight change and breast cancer prognosis</article-title><source>Breast Cancer Res Treat</source><year>2022</year><volume>193</volume><issue>3</issue><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1007/s10549-022-06592-6</pub-id><pub-id pub-id-type="pmid">35435529</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhang YX, Liang ZZ, Li YQ, et al. Association between weight change and breast cancer prognosis. Breast Cancer Res Treat. 2022;193(3):677&#x02013;684.<pub-id pub-id-type="pmid">35435529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Liang ZZ, Zhang YX, Lin Y, et al. Joint effects of multiple sleep characteristics on breast cancer progression by menopausal status. Sleep Med. 2019;54:153&#x02013;158.</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Zhang JY, Liao YH, Lin Y, et al. Effects of tea consumption and the interactions with lipids on breast cancer survival. Breast Cancer Res Treat. 2019;176(3):679&#x02013;686.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Ye HM, Lu MJ, Liu Q, et al. Beneficial Effect of Toxoplasma gondii Infection on the Prognosis of Breast Cancer Was Modified by Cytokines. Clin Epidemiol. 2023;15:469&#x02013;481.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Chen M, Yang P. Toxoplasma gondii gra5 deletion mutant protects hosts against Toxoplasma gondii infection and breast tumors. Front Immunol. 2023 Jun 23;14:1173379.&#x000a0;</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Arias-Calvachi C, Blanco R, Calaf GM, et al. Epstein-Barr Virus Association with Breast Cancer: Evidence and Perspectives. Biology. 2022;11(6):799.</mixed-citation></ref></ref-list></back></article>